Want to see KLRS full AI Analyst Report?
KLRS Stock Chart & Stats
$3.73
-$0.15(-4.02%)
At close: 4:00 PM EDT
$3.73
-$0.15(-4.02%)
Day’s Range― - ―
52-Week Range$2.14 - $11.88
Previous Close$3.5
Volume71.67K
Average Volume (3M)136.22K
Market Cap
$86.00M
Enterprise Value$41.08
Total Cash (Recent Filing)$97.22M
Total Debt (Recent Filing)$1.41M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Nov 18, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.15
Shares Outstanding23,792,278
10 Day Avg. Volume189,046
30 Day Avg. Volume136,224
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.63
Price to Sales (P/S)0.00
P/FCF Ratio-2.98
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$18.67Price Target Upside400.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Differentiation (TH103)Robust Phase 1a structural/functional gains and markedly lower plasma Cmax suggest TH103 may offer longer intraocular durability and favorable safety. Durable dosing advantages and clear biological differentiation can establish sustainable competitive positioning in nAMD and guide Phase 3 dose selection.
Low Financial LeverageVery low reported debt relative to equity limits near-term interest and solvency pressure, preserving flexibility for financing choices. This balance-sheet characteristic reduces bankruptcy risk and supports strategic optionality while the company funds development prior to commercial revenues.
Strengthened Financial LeadershipHiring a CFO with capital markets and biotech equity experience enhances fundraising execution and investor communications. Coupled with an interim accounting lead and clear governance moves, this improves operational continuity and increases probability of more effective future financing and transaction execution.
Bears Say
Pre-revenue With High Cash BurnSustained, sizable operating cash burn and continued pre-revenue status create a structural reliance on external capital. Unless clinical progress is rapid, the company faces recurring financing events that can dilute shareholders and stress execution if market access or terms worsen over multiple funding rounds.
Single-asset Concentration RiskBusiness is concentrated on clinical-stage therapeutics (notably TH103). This single-asset orientation means commercial and valuation outcomes are highly binary; a setback in trials or regulatory review would materially impair future prospects and heighten funding and strategic risks.
Equity Erosion And Historical VolatilityDeclining equity and past episodes of negative equity reflect value erosion and prior funding strain. This reduces the cushion against losses, complicates future financings, can force dilutive capital raises, and signals higher governance and solvency risk relative to peers with more stable equity bases.
Kalaris Therapeutics News
KLRS FAQ
What was Kalaris Therapeutics’s price range in the past 12 months?
Kalaris Therapeutics lowest stock price was $2.14 and its highest was $11.88 in the past 12 months.
What is Kalaris Therapeutics’s market cap?
Kalaris Therapeutics’s market cap is $86.00M.
When is Kalaris Therapeutics’s upcoming earnings report date?
Kalaris Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 98 days.
How were Kalaris Therapeutics’s earnings last quarter?
Kalaris Therapeutics released its earnings results on Aug 11, 2026. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.495 by $0.015.
Is Kalaris Therapeutics overvalued?
According to Wall Street analysts Kalaris Therapeutics’s price is currently Undervalued.
Does Kalaris Therapeutics pay dividends?
Kalaris Therapeutics does not currently pay dividends.
What is Kalaris Therapeutics’s EPS estimate?
Kalaris Therapeutics’s EPS estimate is -0.52.
How many shares outstanding does Kalaris Therapeutics have?
Kalaris Therapeutics has 23,792,278 shares outstanding.
What happened to Kalaris Therapeutics’s price movement after its last earnings report?
Kalaris Therapeutics reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.495. Following the earnings report the stock price went up 0.761%.
Which hedge fund is a major shareholder of Kalaris Therapeutics?
Currently, no hedge funds are holding shares in KLRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kalaris Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.67 (400.45% Upside)
$18.67 (400.45% Upside)
Insider Transactions
Bought Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 8.1%
Last 30 Days ▲ 8.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.99%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.51%
Trailing 12-Months
Company Description
Kalaris Therapeutics
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
KLRS Stock 12 Month Forecast
Average Price Target
$18.67
▲(400.45% Upside)
Technical Analysis
Coherus Biosciences
―
Nektar Therapeutics
―
Cellectis SA
―
Seres Therapeutics
―
Kodiak Sciences
―
Ownership Overview
54.44% Insiders
1.98% Mutual Funds
4.37% Other Institutional Investors
38.07% Public Companies and
Individual Investors